The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors
The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949819826000671?dgcid=rss_sd_all
The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S2949819826000671?dgcid=rss_sd_all
“The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.” ESMO Gastrointestinal Oncology.
@article{article44844,
title = {The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949819826000671?dgcid=rss_sd_all}
}